Abattis signs deal to market CBD-infused kombucha in Colorado, Washington

Related tags Immune system

Abattis signs deal to market CBD-infused kombucha in Colorado, Washington
Abattis Bioceuticals Corp. has signed a letter of intent to produce in the US kombucha infused with cannabidiol (CBD), a non-narcotic compound derived from marijuana, the company announced yesterday. 

The deal, signed with Crudessense Kombucha, envisions building a plant to produce the drink somewhere in the Denver-Boulder area in Colorado, said Abattis CEO Mike Withrow. The drinks would be produced and marketed under the Rise Kombucha name, and the specific product name will be Cannabucha Sun Rise, Withrow said.

Rise Kombucha is already a successful brand sold across Canada, the company said.  The new CBD-infused drink would go on the market first in Washington state and in Colorado, the two states that passed voter initiatives legalizing recreational marijuana use in the most recent election.

"We are very excited to enter into the emerging US CBD infused product markets, leading with a Kombucha beverage which is fast growing in popularity. Kombucha is a perfect delivery beverage for CBD's because it is a functional probiotic drink that strengthens the immune system, balances intestinal flora, stimulates digestion, combats stress, and increases energy,"​ Withrow said.

Cannabidiol has been studied since the 1980s for its anti-inflammatory properties.  More recently, it has been studied for positive effects on airway constriction​ in obstructive breathing disorders.

Related news

Show more

Related products

show more

A Groundbreaking Prebiotic

A Groundbreaking Prebiotic

Content provided by ADM | 12-Mar-2024 | Infographic

PreforPro® is a clinically studied prebiotic that supports the growth of select beneficial bacteria in the gut by utilizing phage technology.

Pomella® Extract: Prebiotic Potential in New Study

Pomella® Extract: Prebiotic Potential in New Study

Content provided by Verdure Sciences | 09-Jan-2024 | White Paper

A new clinical trial evaluated 250mg/day Pomella® for beneficial effects on the gut microbiome, circulating short chain fatty acids, and gut-microbial...

Whitepaper: Discover a new era in postbiotics

Whitepaper: Discover a new era in postbiotics

Content provided by DSM Nutritional Products | 28-Nov-2023 | White Paper

Postbiotic ingredients are set to open up a world of opportunities across the human health and nutrition industry, fueled by developing science demonstrating...

Related suppliers

Follow us

Products

View more

Webinars